Monday, February 19, 2024 9:59:57 AM
Third Quarter 2023
Financial Highlights
Aggregate cash and cash equivalents, restricted cash, short-term investments, and receivables on September 30, 2023 totaled $200.5 million as compared to $654.7 million on December 31, 2022.
Our cash, cash equivalents, restricted cash, and short-term investments on September 30, 2023 was $198.9 million as compared to $648.6 million on December 31, 2022. Accounts receivable and research and development tax credits receivable on September 30, 2023 were $1.6 million as compared to $6.1 million on December 31, 2022.
Our short-term investments consist of U.S. treasury securities.
Our current notes payable balance at September 30, 2023 was $100.0 million, which is due in September 2024.
Based on our current cash and investments position, current operating plans, and with the $100.0 million notes payable due in September 2024, we have sufficient funds to operate into the second half of 2024.
Net loss for the three and nine months ended September 30, 2023 was $21.3 million and $578.4 million, respectively. Net loss for the three and nine months ended September 30, 2022 was $21.4 million and $59.6 million, respectively.
The net loss for the nine months ended September 30, 2023 includes one-time in-process research and development expenses associated with the in-licensing of ivonescimab from Akeso of $520.9 million.
Operating cash outflow for the nine months ended September 30, 2023 and 2022 was $57.3 million and $46.8 million, respectively.
Recent SMMT News
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 • Business Wire • 05/01/2024 11:00:00 AM
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 • Business Wire • 04/24/2024 08:30:00 PM
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors • Business Wire • 04/11/2024 08:30:00 PM
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum • Business Wire • 04/10/2024 11:00:00 AM
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 • Business Wire • 03/22/2024 11:00:00 AM
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 • Business Wire • 03/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:05:09 PM
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:05:51 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 12:55:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 12:32:56 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 02/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:25:38 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:35:18 PM
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024 • Business Wire • 02/14/2024 03:29:00 PM
- Summit Therapeutics to Host Fourth Quarter & Full Year 2023 • Business Wire • 02/14/2024 12:00:00 PM
- Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:07:05 PM
- Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:33:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:22:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:19:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:06:38 PM
- Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/03/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 09:49:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM